COMP <GO>
ACAD vs XENE // FORWARD P/E MULTIPLE
ACADIA Pharmaceuticals Inc. (NASDAQ) VS. Xenon Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: ACAD 8
— XENE 2
▲ FORWARD P/E MULTIPLE LEADER: ACAD
LAST: $20.59 (-0.82%) • MKT CAP: $3.55B
forward-pe
8.5x
LAST: $37.41 (-0.35%) • MKT CAP: $3.62B
forward-pe
29.0x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ACAD VS. XENE)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ACAD | XENE | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 91.70% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 7.90% | -35.00% | +42.90 | ACAD | /roic <GO> |
| EV/EBITDA & P/E Valuation | 31.2x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 2.94% | -7.70% | +10.64 | ACAD | /fcf-yield <GO> |
| Operating Margin | 9.80% | -36.70% | +46.50 | ACAD | /operating-margins <GO> |
| Net Profit Margin | 36.50% | -34.00% | +70.50 | ACAD | /net-margins <GO> |
| Revenue Growth (YoY) | 11.90% | 7.70% | +4.20 | ACAD | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 6.26 | 26.00 | -19.74 | XENE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 5/9 | +2.00 | ACAD | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 45.7 | 44.3 | +1.40 | ACAD | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.10 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 8.5x | 29.0x | -20.50 | ACAD | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $3.55B | $3.62B | -$75.0M | XENE | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ACAD REV | XENE REV | ACAD GROSS % | XENE GROSS % | ACAD FCF | XENE FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.07B | $0 | 91.7% | — | $105.1M | -$279.9M |
| FY 2024 | $957.8M | $0 | 91.5% | — | $157.2M | -$184.5M |
| FY 2023 | $726.4M | $0 | — | — | $16.7M | -$151.1M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ACAD // BETA —
XENE // BETA 1.10